Treatment of Invasively Ventilated Adults With Early Activity and Mobilisation

Phase 3

Completed

• Conditions: Critically Ill, Mechanically Ventilated

• Registration Number: NCT03133377
• Lead Sponsor: Australian and New Zealand Intensive Care Research Centre

Brief Summary

The aim of this study is to evaluate the effect of early activity and mobilisation during prolonged IMV on the composite outcome "days alive and out of hospital to day 180". The effect of the intervention on mortality, physical, cognitive and psychological function at 180 days, as well as cost-effectiveness of the intervention, will also be evaluated. The study will also explore process of care measures and baseline physiology and ICU mobility outcomes.

The hypothesis is that, in ICU patients expected to require prolonged IMV, early activity and mobilisation increases the number of days alive and at home to day 180 when compared with standard care.

Detailed Description

The TEAM Trial is a definitive phase III multi-centre randomised controlled trial in mechanically ventilated patients. Supported by compelling preliminary data, the trial will determine whether early activity and mobilisation during mechanical ventilation improves days alive and at home at 6 months compared to standard care. Recruiting 750 patients, this will be the largest trial ever conducted of early mobilisation.

Patients allocated to the early activity and mobilisation protocol (intervention group) will be assessed by a physiotherapist daily during the ICU stay to determine the highest level of mobility. This will determine the dosage and type of exercise that will be delivered, led by the physiotherapist with assistance from the multidisciplinary team. For both groups, concomitant care will be guided by the treating clinician. In addition, all post-ICU patient management will be at the discretion of the patient's ward-based treating physicians.

Patients will be randomized via web-based system and de-identified data will be collected on the following: baseline demographics; comorbidities; sedatives, analgesics, corticosteroids and neuromuscular blockers; pain/sedation/delirium scores; tracheostomy, intubation and renal replacement therapy. The intervention will be administered during the ICU stay upto 28days and the Day 180 follow up will be conducted centrally.

Study Timeline

• Study First Submitted: 2017-04-10
• Study First Submitted QC: 2017-04-25
• Study First Posted: 2017-04-28
• Study Start: 2018-02-28
• Primary Completion: 2022-05-18
• Study Completion: 2022-11-10
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-14
• Last Update Posted: 2023-12-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

1. Aged 18 years or older.

2. Intubated and expected to remain invasively mechanically ventilated the day after tomorrow.

3. Sufficient cardiovascular stability to make mobilisation potentially possible, as indicated by:

   1. the absence of current brady-arrhythmia requiring pharmacological support
   2. a current ventricular rate ≤ 150 bpm
   3. most recent lactate ≤ 4.0 mmol/L
   4. current combined noradrenaline/adrenaline infusion rate of ≤ 0.2 mcg/kg/min, OR if noradrenaline/adrenaline infusion rate has increased by more than 25% in the last 6 hours, dose must be <0.1 mcg/kg/min.
   5. most recent cardiac index ≥ 2.0 L/min/m2 (where measured)
   6. no current requirement for VA ECMO

4. Sufficient respiratory stability to make mobilisation potentially possible, as indicated by:

   1. current FiO2 ≤ 0.6
   2. current PEEP ≤ 16 cm H20
   3. an absence of current requirement for NO, prone ventilation, neuromuscular blockers, ventilation, prostacyclin, VV ECMO or HFOV
   4. current RR ≤ 45 bpm

Exclusion Criteria

1. Dependent for activities of daily living in the month prior to current ICU admission (gait aids are acceptable).
2. Documented cognitive impairment.
3. Proven or suspected acute primary brain pathology (e.g. traumatic brain injury, stroke, hypoxic brain injury).
4. Proven or suspected spinal cord injury or other neuromuscular disease that will result in permanent or prolonged weakness (not including ICU acquired weakness).
5. Has rest in bed orders and/or has bilateral non-weight bearing orders for the lower limbs.
6. Life expectancy less than 180 days due to a chronic or underlying medical condition.
7. Death is deemed inevitable as a result of the current illness and either the patient or treating clinical or substitute decision maker are not committed to full active treatment.
8. Unable to communicate in the official local language.
9. This is not the first ICU admission in the index hospital admission.
10. Fulfilled all inclusion criteria and none of the exclusion criteria ≥ 72 hours

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of days alive and out of hospital	between randomisation and 180 days	Any days spent in rehabilitation or a nursing home counted as days in hospital

Secondary Outcome Measures

Name	Time	Method
Time from randomisation until death	From date of randomisation unitl date of death from all cause, censored at 180days
All-cause mortality	From date of randomisation up to180days.
ICU-free days	From date of randomisation until day 28	patients who die prior to day 28 will be assigned zero ICU-free days
Ventilator-free days	From date of randomisation until day 28	patients who die prior to day 28 will be assigned zero ventilator-free days
Generic function and disability measured with the World Health Organisation's Disability Assessment Schedule (WHODAS)	Assessed at 180days
Quality of life and health status measured using the European Quality of Life 5 Dimensions 5 Level (EQ5D-5L)	Assessed at 180days
Independent activities of daily living measured with Barthel Activities of Daily Living (ADL) Index and The Lawton Instrumental Activities of Daily Living Scale (IADL)	Assessed at 180days

Trial Locations

Locations (49)

Royal Prince Alfred Hospital; 🇦🇺 Camperdown, New South Wales, Australia

St George Hospital; 🇦🇺 Sydney, New South Wales, Australia

John Hunter Hospital; 🇦🇺 Sydney, New South Wales, Australia

Royal North Shore Hospital; 🇦🇺 Sydney, New South Wales, Australia

Wollongong Hospital; 🇦🇺 Wollongong, New South Wales, Australia

Sunshine Coast University Hospital; 🇦🇺 Birtinya, Queensland, Australia

Mater Health; 🇦🇺 Brisbane, Queensland, Australia

Mater Private Hospital; 🇦🇺 Brisbane, Queensland, Australia

Caboolture Hospital; 🇦🇺 Caboolture, Queensland, Australia

The Prince Charles Hospital; 🇦🇺 Chermside West, Queensland, Australia

Scroll for more (39 remaining)